miR-133a Promotes TRAIL Resistance in Glioblastoma via Suppressing Death Receptor 5 and Activating NF-κB Signaling

Recombinant tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), as a novel cancer therapeutic, is being tested in phase II and III clinical trials; however, TRAIL resistance remains a big obstacle preventing its clinical application. Considering that TRAIL-induced apoptosis throug...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shan-shan, Feng, Lu, Hu, Bao-guang, Lu, Ying-fei, Wang, Wei-mao, Guo, Wei, Suen, Chun-wai, Jiao, Bao-hua, Pang, Jian-xin, Fu, Wei-ming, Zhang, Jin-fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560119/
https://www.ncbi.nlm.nih.gov/pubmed/28918048
http://dx.doi.org/10.1016/j.omtn.2017.07.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560119/
https://www.ncbi.nlm.nih.gov/pubmed/28918048
http://dx.doi.org/10.1016/j.omtn.2017.07.015

Ejemplares similares